Advertisement

Primary CNS Lymphoma

  • Agnieszka KorfelEmail author
Chapter
Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Abstract

Primary CNS lymphoma (PCNSL), a very rare lymphoma subtype confined to the CNS at time of diagnosis, differs from systemic aggressive lymphoma in its low tendency to systemic dissemination, more aggressive course, and less satisfactory outcome. For diagnosis making, a biopsy of a lesion visualized by contrast-enhanced MRI is needed. The optimal treatment for PCNSL has not been established thus far due to paucity of adequately designed trials. High-dose methotrexate-based polychemotherapy is currently considered standard primary treatment for all PCNSL patients who can tolerate it. For consolidation, non-cross-resistant conventional chemotherapy or high-dose chemotherapy followed by stem cell transplantation is most frequently used. Whole-brain radiotherapy is no more routinely used at most centers due to increased risk of delayed CNS toxicity and the lack of overall survival prolongation after combined treatment. The role of intrathecal/intraventricular chemotherapy, optimal salvage treatment, and treatment of immunocompromised patients has not been defined thus far.

Keywords

Aggressive lymphoma Blood-brain barrier Whole-brain irradiation High-dose methotrexate CNS toxicity 

References

  1. 1.
    Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(Suppl 5):v1–49.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    O’Neill BP, Decker PA, Tieu C, et al. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol. 2013;88(12):997–1000.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol. 2013;9(6):317–27.PubMedCrossRefGoogle Scholar
  4. 4.
    Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol. 2011;32(6):984–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Kuker W, Nagele T, Korfel A, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72(2):169–77.PubMedCrossRefGoogle Scholar
  6. 6.
    Yap KK, Sutherland T, Liew E, et al. Magnetic resonance features of primary central nervous system lymphoma in the immunocompetent patient: a pictorial essay. J Med Imaging Radiat Oncol. 2012;56(2):179–86.PubMedCrossRefGoogle Scholar
  7. 7.
    Calli C, Kitis O, Yunten N, et al. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol. 2006;58(3):394–403.PubMedCrossRefGoogle Scholar
  8. 8.
    Toh CH, Castillo M, Wong AM, et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol. 2008;29(3):471–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Zacharia TT, Law M, Naidich TP, et al. Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging. 2008;18(4):411–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Harting I, Hartmann M, Jost G, et al. Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett. 2003;342(3):163–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Kawai N, Miyake K, Yamamoto Y, et al. 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma. Biomed Res Int. 2013;2013:247152.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Palmedo H, Urbach H, Bender H, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging. 2006;33(2):164–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16(7):e322–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Cinque P, et al. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphomas of the central nervous system. Lancet. 1993;342:398–401.PubMedCrossRefGoogle Scholar
  15. 15.
    Deckert M, Engert A, Brück W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25(12):1797–807.PubMedCrossRefGoogle Scholar
  16. 16.
    Korfel A, Weller M, Martus P, et al. Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. Ann Oncol. 2012;23(9):2374–80.PubMedCrossRefGoogle Scholar
  17. 17.
    Schroers R, Baraniskin A, Heute C, et al. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol. 2010;85(6):520–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Fischer L, Korfel A, Pfeiffer S, et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009;15(19):5968–73.PubMedCrossRefGoogle Scholar
  20. 20.
    Rubenstein JL, Wong VS, Kadoch C, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013;121(23):4740–8.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Strehlow F, Bauer S, Martus P, et al. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. J Neurooncol. 2016;129(1):165–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Viaccoz A, Ducray F, Tholance Y, et al. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. Neuro Oncol. 2015;17(11):1497–503.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16(11):1589–99.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008;71(17):1355–60.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266–72.PubMedCrossRefGoogle Scholar
  26. 26.
    Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–47.PubMedCrossRefGoogle Scholar
  27. 27.
    Weller M, Martus P, Roth P, et al. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol. 2012;14(12):1481–4.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23:9–17.PubMedCrossRefGoogle Scholar
  29. 29.
    Borsi JD, Moe PJ. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer. 1987;60(1):5–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20.PubMedCrossRefGoogle Scholar
  31. 31.
    Herrlinger U, Schabet M, Brugger W, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol. 2002;51(2):247–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Batchelor T, Carson K, O’Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–27.PubMedCrossRefGoogle Scholar
  34. 34.
    DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20(24):4643.PubMedCrossRefGoogle Scholar
  35. 35.
    Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21(24):4483–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061–8.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Illerhaus G, Kasenda B, Ihorst G, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016;3(8):e388–97.PubMedCrossRefGoogle Scholar
  39. 39.
    Ferreri A, Cwynarski K, Pulczynski E, et al. Effects on survival and neurocognitive functions of whole-brain radiotherapy (WBRT) and autologous stem cell transplantation (ASCT) as consolidation options after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary CNS lymphoma (PCNSL): results of the second randomization of the IELSG32 trial. Blood. 2016;128:511.Google Scholar
  40. 40.
    Korfel A, Thiel E, Martus P, et al. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015;84(12):1242–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Herrlinger U, Schäfer N, Fimmers R, et al. Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol. 2017;143(9):1815–21.PubMedCrossRefGoogle Scholar
  42. 42.
    Correa DD, DeAngelis LM, Shi W, et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology. 2004;62(4):548–55.PubMedCrossRefGoogle Scholar
  43. 43.
    Doolittle ND, Korfel A, Lubow MA, et al. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology. 2013;81(1):84–92.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Juergens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 2010;67:182–1899.PubMedCrossRefGoogle Scholar
  45. 45.
    Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21(24):4489–95.PubMedCrossRefGoogle Scholar
  46. 46.
    Rieger L, Schlegel U, Le Coutre P, et al. A head-to-head comparison of two different high dose methotrexate (HDMTX)—and high dose cytarabin (HDAraC)-based chemotherapy regimens in younger patients with primary central nervous system lymphoma (PCNSL). Oral presentation at WFNOS 2017 Meeting, 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies, May 4–7, 2017, Zurich, Switzerland.Google Scholar
  47. 47.
    Hoang-Xuan K, Taillandier L, Chinot O, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003;21(14):2726–31.PubMedCrossRefGoogle Scholar
  48. 48.
    Illerhaus G, Marks R, Müller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009;20(2):319–25.PubMedCrossRefGoogle Scholar
  49. 49.
    Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009;11(2):211–5.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Olivier G, Clavert A, Lacotte-Thierry L. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial. Am J Hematol. 2014;89(11):1024–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Omuro A, Chinot O, Taillandier L, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015;2(6):e251–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31(4):846–52.PubMedCrossRefGoogle Scholar
  53. 53.
    Pulczynski EJ, Kuittinen O, Erlanson M, et al. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica. 2015;100(4):534–40.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003;17(12):1787–93.PubMedCrossRefGoogle Scholar
  55. 55.
    Evens AM, Choquet S, Kroll-Desrosiers AR, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant. 2013;13(6):1512–22.PubMedCrossRefGoogle Scholar
  56. 56.
    Pentsova E, Deangelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol. 2014;117(1):161–5.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004;10(17):5643–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM, et al. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol. 2003;70(4):219–24.PubMedCrossRefGoogle Scholar
  59. 59.
    Chamberlain MC. Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. J Neurooncol. 2014;118(1):155–62.PubMedCrossRefGoogle Scholar
  60. 60.
    Chamberlain MC. High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma. J Neurooncol. 2016;126(3):545–50.PubMedCrossRefGoogle Scholar
  61. 61.
    Enting RH, Demopoulos A, DeAngelis LM, et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004;63(5):901–3.PubMedCrossRefGoogle Scholar
  62. 62.
    Fischer L, Thiel E, Klasen HA, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006;17(7):1141–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Maza S, Kiewe P, Munz DL, et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol. 2009;11(4):423–9.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Nayak L, Abrey LE, Drappatz J, et al. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013;54(1):58–61.PubMedCrossRefGoogle Scholar
  65. 65.
    Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007;96(6):864–7.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Korfel A, Schlegel U, Herrlinger U, et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. J Clin Oncol. 2016;34(15):1757–63.PubMedCrossRefGoogle Scholar
  67. 67.
    Kasenda B, Ihorst G, Schroers R, et al. High-dose chemotherapy with autologous hematopoietic stem cell support for relapsed or refractory primary CNS lymphoma—a prospective multicentre trial by the German Cooperative PCNSL Study Group. Leukemia. 2017;31(12):2623–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26(15):2512–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Hottinger AF, DeAngelis LM, Yahalom J, et al. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology. 2007;69(11):1178–82.PubMedCrossRefGoogle Scholar
  70. 70.
    Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005;23(7):1507–13.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Hematology, Oncology, and Tumor ImmunologyCharite Universitätsmedizin BerlinBerlinGermany

Personalised recommendations